( Previously posted today but putting into this thread title makes more sense -apologies in advance but dosent belong in weekly chart thread IMO !) @FewPennies -
maybe you can post your coverage or consolidation post of events in this thread for the wider investment community to see as we can still gain additional market exposure here 
People - for the new ones now coming on board IMU (including myself !) before she breaks out majorly and becomes a 500 mill market cap over night because thats what will happen if we get a partnership deal around $500 million - which is an average industry price paid for these types of deals. Now we may get an up front 50 mill if a partnership arrises - time will tell
i firmly believe this announcement below is why a major partnership will show up shortly - especially now they applied for broad platform patents
this is most certainly a paradigm shift in cancer play using B cells - Boom !
Paradigm shift in treatment utilises a patient’s B cells to produce antibodies against regulatory check-point targets • Vaccine mimics check-point inhibitors – a multi billion-dollar drug class • Broad platform patent filed to protect method of treatment
MELBOURNE Australia 12 February, 2018: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, announces completion of early development of a new mimotope vaccine that will target and compete in the billion-dollar blockbuster anti-PD-1 immuno-oncology market. This announcement follows 18 months of intensive research conducted in partnership with the Medical University of Vienna.
A mimotope induces an antibody reaction against a target, in this case, a regulatory immune check-point known as PD-1. Mimotope induced antibodies may have advantages over synthetic antibodies including, safety, longer responses, memory and cost. The check-point inhibitor market is dominated by two monoclonal antibody drugs, Opdivo (marketed by BMS) and Keytruda (marketed by Merck).
Sales reported for Opdivo and Keytruda in 2017 were USD4.95b and USD3.81b respectively with double digit annual growth. Both drugs target PD-1, a key switch of the immune system’s ability to find and eliminate cancerous cells. The ground-breaking research from Vienna, conducted under the leadership of Imugene’s CSO Professor Dr Ursula Wiedermann, has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform, generate antibodies that bind to the PD-1 biomarker. PD-1 antibodies block a protective mechanism on cancer cells, and allow the immune system to destroy those cancer cells. The concept of teaching and inducing the body to generate its own antibodies against PD-1 expressing cells represents a paradigm shift in immuno-oncology, and is the first report of treating cancer by this method.
A new method of treatment patent (Australian Patent Office: 2018900368) has been filed to provide protection across a broad landscape of possible immunotherapies, including their combination with cancer vaccines such as HER-Vaxx. Imugene will now commence a preclinical development program which will test the vaccine for both efficacy and safety. This program will be intensive yet systematic to yield a clinical-ready vaccine candidate. Professor Dr Ursula Wiedermann and Imugene CEO Leslie Chong said in a joint announcement “Development of this new immunotherapy has positioned Imugene to be a new and competitive player in the immuno-oncology revolution in cancer therapy. This expands our pipeline and transforms Imugene into a multi-asset biopharmaceutical company.” Leslie Chong added “On announcing our mimotope program in January 2016 we were cautious given the early stage of the research. However, the progress made by the entire team raises the anticipation that a paradigm shift in cancer treatment is in play.”
(20min delay)